The long tail and rare disease research: the impact of next-generation sequencing for rare Mendelian disorders
- 14 September 2015
- journal article
- research article
- Published by Hindawi Limited in Genetics Research
- Vol. 97, e15
Abstract
Summary: There are an estimated 6000–8000 rare Mendelian diseases that collectively affect 30 million individuals in the United States. The low incidence and prevalence of these diseases present significant challenges to improving diagnostics and treatments. Next-generation sequencing (NGS) technologies have revolutionized research of rare diseases. This article will first comment on the effectiveness of NGS through the lens of long-tailed economics. We then provide an overview of recent developments and challenges of NGS-based research on rare diseases. As the quality of NGS studies improve and the cost of sequencing decreases, NGS will continue to make a significant impact on the study of rare diseases moving forward.Keywords
This publication has 87 references indexed in Scilit:
- Next-Generation Sequencing Identifies Transportin 3 as the Causative Gene for LGMD1FPLOS ONE, 2013
- An integrated encyclopedia of DNA elements in the human genomeNature, 2012
- Cloud computing and the DNA data raceNature Biotechnology, 2010
- Microdroplet-based PCR enrichment for large-scale targeted sequencingNature Biotechnology, 2009
- Clinical research for rare disease: Opportunities, challenges, and solutionsMolecular Genetics and Metabolism, 2009
- Accurate whole human genome sequencing using reversible terminator chemistryNature, 2008
- Next-generation DNA sequencingNature Biotechnology, 2008
- The potential and challenges of nanopore sequencingNature Biotechnology, 2008
- Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controlsNature, 2007
- Identification of the breast cancer susceptibility gene BRCA2Nature, 1995